Tirzepatide
Dosage30mg
Rp 1.990.000per vial
Cold-chain delivery to your door around Bali. Pens and bacteriostatic water available, just ask.
- Class
- Dual agonist (GIP / GLP-1)
- Half-life
- ~5 days (reported)
Also known as LY3298176, Mounjaro, Zepbound
An approved medicine for this use in some countries. Supplied here for research use only.
FDA-approved (Mounjaro for type 2 diabetes, Zepbound for obesity). Tier-1 evidence: multiple large human trials RCTs across type 2 diabetes, obesity, OSA, HFpEF and advanced fatty-liver disease (MASH), with heart-and-blood-vessel outcomes (human trialsCVOT) published 2025.
About this peptide
Tirzepatide is a dual-agonist peptide that acts on two appetite and metabolism pathways at once, GIP and GLP-1, where Semaglutide hits one and Retatrutide three. It is the most thoroughly studied compound in this class, backed by large human trial programmes across diabetes, obesity and sleep apnoea. The same molecule is an approved medicine in some countries; what we supply is for research use only. Supplied as a freeze-dried powder for research use.
What it does
Researched for substantial fat loss and blood-sugar control, and it is the benchmark the rest of the class is measured against. The weight-loss crowd and bodybuilders leaning out run it for strong appetite suppression and steady fat reduction without the harshness of older fat-loss drugs; the metabolic-health and longevity crowd run it for glucose control and the cardiometabolic markers that improved across its trials. Studied for metabolic research, not muscle growth.
What to expect
Week 1
Appetite suppression within 24-48 hours of first 2.5 mg dose; mild-moderate digestive (nausea, eructation, loose stool or constipation); minimal weight change.
Weeks 2-4
Entrenched appetite suppression; ~1-2 lb/week typical weight loss; digestive events wane.
Weeks 4-12
Each titration step provokes brief digestive recurrence; weight-loss trajectory steepens; lipid/blood pressure/an inflammation marker (hsCRP) improvements visible by ~week 12.
Long term
human trials: -16.0/-21.4/-22.5% at 72 weeks for 5/10/15 mg. 3-year extension: most achieve durable maintenance while on-drug. Cold-turkey discontinuation leading to 82% regain at least 25% of lost weight at 1 y (human trials).
A rough guide drawn from research and community reports. Individual results vary and nothing here is a promise.
Reported effects
Reported benefits
Side effects & cautions
Key points
Best suited to people with real weight or metabolic goals who want the most established compound in the category, including those new to this class who want a proven starting point rather than the newest option. Those chasing the maximum reported effect, or who have plateaued, often step up to Retatrutide. Less of a fit for someone after a small cosmetic cut, where a gentler approach makes more sense.
It activates the GIP and GLP-1 receptors together. GLP-1 curbs appetite and slows gastric emptying, while GIP adds further effects on insulin response and how the body handles fat. Acting on both pathways at once is what research links to its effect on body weight and glucose.
Gastrointestinal effects, mainly nausea, are the most commonly reported in trials and track with how quickly the amount is raised, and appetite can rebound strongly after stopping. The version here is for research use only, not the regulated pharmaceutical product, so purity and correct reconstitution matter. A Certificate of Analysis is shared where our supplier provides one.
Supplied freeze-dried. Reconstitute with bacteriostatic water to your required concentration, then refrigerate at 2-8°C and avoid freezing once mixed; unmixed vials are stable kept cool and dark. We can reconstitute to spec for you as a paid service, or fill a pen.
- Blood pressure
- Lipid / blood pressure / an inflammation marker (hsCRP) improvements
- Heart rate
- No significant effect reported
- Blood sugar
- long-term blood-sugar marker (HbA1c) reduction
- Lipids / cholesterol
- Lipid / blood pressure / an inflammation marker (hsCRP) improvements
What studies and users commonly report happening to these markers. Research context only, not medical advice.
Questions about Tirzepatide
It is the same molecule, but supplied as a research peptide for research use only, not as the regulated prescription medicine. We make no therapeutic claims and nothing here is a substitute for medical care.
Tirzepatide acts on two pathways and has the larger body of human evidence; Retatrutide acts on three and has reported larger weight reductions but is newer. Many regard Tirzepatide as the more established option.
Evidence
Further reading
Want to go deeper? We've written up the research on this.
Sourcing
Sourced carefully from vetted suppliers. Where a Certificate of Analysis is available we share it on request, and we'll always tell you what we have for your batch.
For Research Use Only
Sold strictly for laboratory and research purposes. Not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic application.
